Premium
ICRF‐193, a catalytic inhibitor of DNA topoisomerase II, delays the cell cycle progression from metaphase, but not from anaphase to the G1 phase in mammalian cells
Author(s) -
Iwai Miwako,
Hara Akira,
Andoh Toshiwo,
Ishida Ryoji
Publication year - 1997
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(97)00282-2
Subject(s) - anaphase , metaphase , cell cycle progression , cell cycle , topoisomerase , microbiology and biotechnology , chemistry , mitosis , dna , cell , chromosome , biology , biochemistry , gene
We have shown previously that ICRF‐193, a catalytic inhibitor of DNA topoisomerase II (topo II), delays cell cycle progression in HeLa S3 cells. We report here that the delay of the transition in M phase is observed when HeLa S3 cells were treated with ICRF‐193 during metaphase, but not thereafter. ICRF‐193 also delayed the degradation of cyclin B in the transition from M to G1 phase, while in Chinese hamster ovary (CHO) cells the drug did not delay the progression in M phase. Since HeLa S3 and CHO cells are ‘stringent’ and ‘relaxed’ in mitotic control, respectively, it is suggested that under topo II inhibition, the M phase checkpoint operates through an inability for chromosome segregation.